- Home
- MTAL vs VIR Comparison
MTAL vs VIR Comparison
Compare MTAL & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTAL
- VIR
- Stock Information
- Founded
- MTAL 2021
- VIR 2016
- Country
- MTAL Jersey
- VIR United States
- Employees
- MTAL N/A
- VIR N/A
- Industry
- MTAL Blank Checks
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- MTAL Finance
- VIR Health Care
- Exchange
- MTAL Nasdaq
- VIR Nasdaq
- Market Cap
- MTAL 1.0B
- VIR 706.4M
- IPO Year
- MTAL 2021
- VIR 2019
- Fundamental
- Price
- MTAL $12.21
- VIR $4.95
- Analyst Decision
- MTAL Hold
- VIR Strong Buy
- Analyst Count
- MTAL 4
- VIR 11
- Target Price
- MTAL $12.08
- VIR $25.73
- AVG Volume (30 Days)
- MTAL 1.4M
- VIR 1.5M
- Earning Date
- MTAL 11-09-2025
- VIR 10-30-2025
- Dividend Yield
- MTAL N/A
- VIR N/A
- EPS Growth
- MTAL N/A
- VIR N/A
- EPS
- MTAL N/A
- VIR N/A
- Revenue
- MTAL $321,804,000.00
- VIR $19,000,000.00
- Revenue This Year
- MTAL $17.39
- VIR N/A
- Revenue Next Year
- MTAL $24.69
- VIR $11.08
- P/E Ratio
- MTAL N/A
- VIR N/A
- Revenue Growth
- MTAL N/A
- VIR N/A
- 52 Week Low
- MTAL $7.69
- VIR $4.16
- 52 Week High
- MTAL $14.31
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- MTAL 64.14
- VIR 49.88
- Support Level
- MTAL $12.12
- VIR $4.75
- Resistance Level
- MTAL $12.22
- VIR $5.07
- Average True Range (ATR)
- MTAL 0.02
- VIR 0.27
- MACD
- MTAL 0.00
- VIR -0.02
- Stochastic Oscillator
- MTAL 90.00
- VIR 22.52
About MTAL Metals Acquisition Limited
MAC Copper Ltd is a company focused on operating and acquiring metals and mining businesses in high-quality, stable jurisdictions that are critical in the electrification and decarbonization of the world-wide economy.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.